Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo sobre a tolerabilidade, segurança e eficácia de asciminibe em doentes com leucemia mieloide crónica com cromossoma Filadélfia positivo em fase crónica na Alemanha (ASC2ADHERE)

5 de novembro de 2026 atualizado por: Novartis Pharmaceuticals

Um Estudo Não-Intervencional sobre a Tolerabilidade, Segurança e Eficácia do Asciminib em Pacientes Recentemente Diagnosticados e Pré-tratados com Leucemia Mieloide Crônica Cromossomo Filadélfia-Positivo em Fase Crônica na Alemanha - o Estudo ASC2ADHERE

The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).

Visão geral do estudo

Status

Recrutamento

Tipo de estudo

Observacional

Inscrição (Estimado)

380

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Novartis Pharmaceuticals

Locais de estudo

      • Amberg, Alemanha, 92224
        • Recrutamento
        • Novartis Investigative Site
      • Bad Friedrichshall, Alemanha, 74177
        • Recrutamento
        • Novartis Investigative Site
      • Bad Liebenwerda, Alemanha, 04924
        • Recrutamento
        • Novartis Investigative Site
      • Bad Saarow, Alemanha, 15526
        • Recrutamento
        • Novartis Investigative Site
      • Berlin, Alemanha, 10437
        • Recrutamento
        • Novartis Investigative Site
      • Berlin, Alemanha, 10365
        • Recrutamento
        • Novartis Investigative Site
      • Berlin, Alemanha, 12552
        • Recrutamento
        • Novartis Investigative Site
      • Berlin, Alemanha, 10559
        • Recrutamento
        • Novartis Investigative Site
      • Berlin, Alemanha, 12487
        • Recrutamento
        • Novartis Investigative Site
      • Bremerhaven, Alemanha, 27568
        • Recrutamento
        • Novartis Investigative Site
      • Buchholz Nordheide, Alemanha, 21244
        • Recrutamento
        • Novartis Investigative Site
      • Cottbus, Alemanha, 03046
        • Recrutamento
        • Novartis Investigative Site
      • Deggendorf, Alemanha, 94469
        • Recrutamento
        • Novartis Investigative Site
      • Detmold, Alemanha, 32756
        • Recrutamento
        • Novartis Investigative Site
      • Dorfen, Alemanha, 84405
        • Recrutamento
        • Novartis Investigative Site
      • Dortmund, Alemanha, 44263
        • Recrutamento
        • Novartis Investigative Site
      • Dresden, Alemanha, 01307
        • Recrutamento
        • Novartis Investigative Site
      • Dresden, Alemanha, 01127
        • Recrutamento
        • Novartis Investigative Site
      • Düren, Alemanha, 52353
        • Recrutamento
        • Novartis Investigative Site
      • Erfurt, Alemanha, 99085
        • Recrutamento
        • Novartis Investigative Site
      • Erfurt, Alemanha, 99084
        • Recrutamento
        • Novartis Investigative Site
      • Eschweiler, Alemanha, 52249
        • Recrutamento
        • Novartis Investigative Site
      • Göttingen, Alemanha, 37073
        • Recrutamento
        • Novartis Investigative Site
      • Hanover, Alemanha, 30161
        • Recrutamento
        • Novartis Investigative Site
      • Hanover, Alemanha, 30625
        • Recrutamento
        • Novartis Investigative Site
      • Hildesheim, Alemanha, 31135
        • Recrutamento
        • Novartis Investigative Site
      • Kiel, Alemanha, 24105
        • Recrutamento
        • Novartis Investigative Site
      • Leipzig, Alemanha, 04103
        • Recrutamento
        • Novartis Investigative Site
      • Leverkusen, Alemanha, 51375
        • Recrutamento
        • Novartis Investigative Site
      • Mutlangen, Alemanha, 73557
        • Recrutamento
        • Novartis Investigative Site
      • Naunhof, Alemanha, 04683
        • Recrutamento
        • Novartis Investigative Site
      • Neuss, Alemanha, 41462
        • Recrutamento
        • Novartis Investigative Site
      • Offenburg, Alemanha, 77654
        • Recrutamento
        • Novartis Investigative Site
      • Oldenburg, Alemanha, 26121
        • Recrutamento
        • Novartis Investigative Site
      • Parchim, Alemanha, 19370
        • Recrutamento
        • Novartis Investigative Site
      • Potsdam, Alemanha, 14467
        • Recrutamento
        • Novartis Investigative Site
      • Potsdam, Alemanha, 14482
        • Recrutamento
        • Novartis Investigative Site
      • Schorndorf, Alemanha, 73614
        • Recrutamento
        • Novartis Investigative Site
      • Schwetzingen, Alemanha, 68723
        • Recrutamento
        • Novartis Investigative Site
      • Soest, Alemanha, 59494
        • Recrutamento
        • Novartis Investigative Site
      • Stade, Alemanha, 21680
        • Recrutamento
        • Novartis Investigative Site
      • Torgau, Alemanha, 04860
        • Recrutamento
        • Novartis Investigative Site
      • Ulm, Alemanha, 89081
        • Recrutamento
        • Novartis Investigative Site
      • Wetzlar, Alemanha, 35578
        • Recrutamento
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Baden-Baden, Baden-Wurttemberg, Alemanha, 76532
        • Recrutamento
        • Novartis Investigative Site
      • Heidenheim, Baden-Wurttemberg, Alemanha, 89522
        • Recrutamento
        • Novartis Investigative Site
      • Schwäbisch Hall, Baden-Wurttemberg, Alemanha, 74523
        • Recrutamento
        • Novartis Investigative Site
      • Winnenden, Baden-Wurttemberg, Alemanha, 71364
        • Recrutamento
        • Novartis Investigative Site
    • Bavaria
      • Aschaffenburg, Bavaria, Alemanha, 63739
        • Recrutamento
        • Novartis Investigative Site
      • Augsburg, Bavaria, Alemanha, 86152
        • Recrutamento
        • Novartis Investigative Site
      • Donauwörth, Bavaria, Alemanha, 86609
        • Recrutamento
        • Novartis Investigative Site
      • Herrsching am Ammersee, Bavaria, Alemanha, 82211
        • Recrutamento
        • Novartis Investigative Site
      • Kempten (Allgäu), Bavaria, Alemanha, 87439
        • Recrutamento
        • Novartis Investigative Site
      • Landsberg am Lech, Bavaria, Alemanha, 86899
        • Recrutamento
        • Novartis Investigative Site
      • Munich, Bavaria, Alemanha, 81241
        • Recrutamento
        • Novartis Investigative Site
      • Munich, Bavaria, Alemanha, 81377
        • Recrutamento
        • Novartis Investigative Site
      • Regensburg, Bavaria, Alemanha, 93053
        • Recrutamento
        • Novartis Investigative Site
    • Free Hanseatic City of Bremen
      • Bremerhaven, Free Hanseatic City of Bremen, Alemanha, 27576
        • Recrutamento
        • Novartis Investigative Site
    • Hesse
      • Kassel, Hesse, Alemanha, 34125
        • Recrutamento
        • Novartis Investigative Site
      • Offenbach, Hesse, Alemanha, 63065
        • Recrutamento
        • Novartis Investigative Site
    • Lower Saxony
      • Goslar, Lower Saxony, Alemanha, 38642
        • Recrutamento
        • Novartis Investigative Site
      • Rotenburg (Wümme), Lower Saxony, Alemanha, 27356
        • Recrutamento
        • Novartis Investigative Site
      • Twistringen, Lower Saxony, Alemanha, 27239
        • Recrutamento
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Alemanha, 50674
        • Recrutamento
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Alemanha, 50677
        • Recrutamento
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Alemanha, 51103
        • Recrutamento
        • Novartis Investigative Site
      • Solingen, North Rhine-Westphalia, Alemanha, 42653
        • Recrutamento
        • Novartis Investigative Site
      • Wesel, North Rhine-Westphalia, Alemanha, 46483
        • Recrutamento
        • Novartis Investigative Site
    • Saxony
      • Zittau, Saxony, Alemanha, 02763
        • Recrutamento
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Alemanha, 06110
        • Recrutamento
        • Novartis Investigative Site
      • Merseburg, Saxony-Anhalt, Alemanha, 06217
        • Recrutamento
        • Novartis Investigative Site
    • Schleswig-Holstein
      • Oldenburg in Holstein, Schleswig-Holstein, Alemanha, 23758
        • Recrutamento
        • Novartis Investigative Site
    • Thuringia
      • Altenburg, Thuringia, Alemanha, 04600
        • Recrutamento
        • Novartis Investigative Site
      • Saalfeld, Thuringia, Alemanha, 07318
        • Recrutamento
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 100 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.

Descrição

Inclusion criteria:

  1. Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
  2. Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
  3. Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
  4. Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
  5. Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.

Exclusion criteria:

  1. Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:

    • In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).

    • In second-line treatment:

      • known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
      • presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
  2. Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.

  3. Patients currently participating in an interventional clinical trial.

  4. Patients unable or unwilling to provide written informed consent.

  5. Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.

  6. Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.

  7. The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Asciminib Cohort

Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib.

Imatinib Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment.

Second-generation TKI Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Prazo: Month 12

MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS).

Month 12

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentagem de Pacientes por Razão para a Decisão de Tratamento com TKI Documentada pelo Médico Assistente
Prazo: <!-- Base -->

Basal

<!-- Base -->

Basal

Percentagem de doentes com redução da dose por motivo de redução da dose
Prazo: 3, 6, 9, 12, 15, 18, 21 e 24 meses
3, 6, 9, 12, 15, 18, 21 e 24 meses
Percentagem de Pacientes com Interrupção do Tratamento por Motivo da Interrupção
Prazo: 3, 6, 9, 12, 15, 18, 21 e 24 meses
3, 6, 9, 12, 15, 18, 21 e 24 meses
Percentagem de Doentes que Descontinuaram o Tratamento por Motivo de Descontinuação
Prazo: 3, 6, 9, 12, 15, 18, 21 e 24 meses
3, 6, 9, 12, 15, 18, 21 e 24 meses
Tempo até a Descontinuação do Tratamento
Prazo: 3, 6, 9, 12, 15, 18, 21 e 24 meses
3, 6, 9, 12, 15, 18, 21 e 24 meses
Tempo até Interrupção do Tratamento
Prazo: 3, 6, 9, 12, 15, 18, 21 e 24 meses
3, 6, 9, 12, 15, 18, 21 e 24 meses
Tempo até Redução da Dose
Prazo: 3, 6, 9, 12, 15, 18, 21 e 24 meses
3, 6, 9, 12, 15, 18, 21 e 24 meses
Tempo para a Descontinuação do Tratamento devido a Eventos Adversos (TDCEA)
Prazo: 3, 6, 9, 12, 15, 18, 21 e 24 meses
3, 6, 9, 12, 15, 18, 21 e 24 meses
Percentage of Patients by Clinical Characteristic
Prazo: Baseline

Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status.

Baseline
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Prazo: Month 3

EMR is defined as BCR::ABL1 ≤10% IS.

Month 3
Percentage of Patients With Molecular Response 2 (MR2)
Prazo: 3, 6, 9, 12, 15, 18, 21, and 24 months

MR2 is defined as BCR::ABL1 ≤1% IS.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With MMR
Prazo: 3, 6, 9, 15, 18, 21, and 24 months

MMR is defined as BCR::ABL1 ≤0.1% IS.

3, 6, 9, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.0
Prazo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.5
Prazo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR5
Prazo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Medication Adherence Report Scale (MARS-5) Score
Prazo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Prazo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Prazo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30.

The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100.

A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction.

3, 6, 9, 12, 15, 18, 21, and 24 months
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Prazo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity.

3, 6, 9, 12, 15, 18, 21, and 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de abril de 2026

Conclusão Primária (Estimado)

30 de setembro de 2030

Conclusão do estudo (Estimado)

30 de setembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

16 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de abril de 2026

Primeira postagem (Real)

24 de abril de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever